about
Theoretical Approaches to Lentiviral Mediated Neurotrophin Delivery in Potential Treatments of Parkinson's DiseaseDisorders of the oral cavity in Parkinson's disease and parkinsonian syndromesBehavioral and monoamine perturbations in adult male mice with chronic inflammation induced by repeated peripheral lipopolysaccharide administration.Prostanoid receptor EP2 as a therapeutic targetCentral pathways causing fatigue in neuro-inflammatory and autoimmune illnesses.Brain region-specific alterations in the gene expression of cytokines, immune cell markers and cholinergic system components during peripheral endotoxin-induced inflammation.The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disordersNoninvasive molecular imaging of neuroinflammationDecrease of gene expression of astrocytic 5-HT2B receptors parallels development of depressive phenotype in a mouse model of Parkinson's disease.Peripheral challenge with a viral mimic upregulates expression of the complement genes in the hippocampus.Time-dependent behavioral, neurochemical, and metabolic dysregulation in female C57BL/6 mice caused by chronic high-fat diet intake.TIR-Domain-Containing Adapter-Inducing Interferon-β (TRIF) Is Essential for MPTP-Induced Dopaminergic Neuroprotection via Microglial Cell M1/M2 Modulation.Inflammation and adaptive immunity in Parkinson's disease.Blood-brain barrier dysfunction-induced inflammatory signaling in brain pathology and epileptogenesisInfluenza infection triggers disease in a genetic model of experimental autoimmune encephalomyelitis.Mitochondrial control of cell bioenergetics in Parkinson's disease.A20 in Multiple Sclerosis and Parkinson's Disease: Clue to a Common Dysregulation of Anti-Inflammatory Pathways?Peripheral Inflammation and Demyelinating Diseases.Peripheral viral challenge elevates extracellular glutamate in the hippocampus leading to seizure hypersusceptibility.Coffee consumption is associated with DNA methylation levels of human blood.Brain and Peripheral Atypical Inflammatory Mediators Potentiate Neuroinflammation and Neurodegeneration.Periodontal inflammatory disease is associated with the risk of Parkinson's disease: a population-based retrospective matched-cohort study.Qigong Exercise May Reduce Serum TNF-α Levels and Improve Sleep in People with Parkinson's Disease: A Pilot Study.The putative role of environmental aluminium in the development of chronic neuropathology in adults and children. How strong is the evidence and what could be the mechanisms involved?Why is there motor deterioration in Parkinson's disease during systemic infections-a hypothetical view.Chronic airway-induced allergy in mice modifies gene expression in the brain toward insulin resistance and inflammatory responses.Vertebrate food products as a potential source of prion-like α-synuclein.Parkinson's disease: experimental models and reality.Comparison of neutrophil-lymphocyte ratio (NLR) in Parkinson's disease subtypes.Neutrophil-mediated delivery of nanotherapeutics across blood vessel barrier.Involvement of c-Abl Kinase in Microglial Activation of NLRP3 Inflammasome and Impairment in Autolysosomal System.Systemic inflammation induced by lipopolysaccharide aggravates inherited retinal dystrophy.Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson's disease treatment.Partial Depletion of Peripheral M1 Macrophages Reverses Motor Deficits in MPTP-Treated Mouse by Suppressing Neuroinflammation and Dopaminergic Neurodegeneration.Co-aggregation of pro-inflammatory S100A9 with α-synuclein in Parkinson's disease: ex vivo and in vitro studies.The Healing Effect of Human Milk Fat Globule-EGF Factor 8 Protein (MFG-E8) in A Rat Model of Parkinson's Disease
P2860
Q26746174-DE5C2E2A-80E3-46C0-B57C-F4DD1A2F1A32Q28082795-5C999606-8FE0-4C8A-AC59-AF703E08B226Q30719160-F358C3B6-69DD-4FB2-B060-4EC7931C513EQ33711678-28F69342-890A-4DE0-ABA8-6AFD43A08594Q35059951-208D5756-F0E8-42F0-BC69-E5537A432485Q35192822-EB18188D-54C8-4B96-B8C9-6C1BF5CAC4D9Q35246024-708E8AB7-9CD0-457A-B122-7CA5678E13E6Q36079268-73915B4C-6E6A-478E-AD0C-DC51D19D7B12Q36124822-A6DB635C-D45A-43DB-8365-BE9CDC7C1E2CQ36358504-79454649-3E29-4B48-A568-2423EB2B4724Q36665054-F5337751-4D88-49B8-989B-511771E6C44EQ37656913-559C7454-6660-44E8-8623-1EE8E8A2CB95Q37982378-5F579346-42BC-4E4B-89B2-BD297BAEB2B2Q38058374-94FC8768-ACB3-47DB-B2A3-787F37374FFFQ38684427-24ECFDF0-BD8F-48F6-AB8F-2056079DE56BQ38811534-6B31436D-516F-4E8B-8F87-7781D35F7281Q38880527-06B2F474-71F4-46E4-9D82-175953876643Q38974745-D3AFCE82-7AD1-492E-B46C-735699885117Q40314820-D0DEC147-E7D7-47EB-8521-9D9FED62645EQ40335664-CD18D125-4547-422B-84EF-875780A27DF8Q41097407-3B313022-562D-4D4E-8111-6E88C6D393D5Q41371529-0D849E9B-5520-45A9-B8D3-EC8E02825F71Q41529537-6506256C-6529-4D3C-AAE1-797E47462A0AQ41689625-BC970A8A-EEC8-40C7-AF20-9080B8D27316Q42334435-F33DC1BC-CE1E-4E4D-B03E-B5CF43E2996DQ42563794-B8185548-220B-402E-863D-0AF85808324DQ46252338-8C46D890-90D9-4D28-866C-FA19CE3EA969Q47389506-AAC5A07C-1E24-442B-8C44-0190BC19EB74Q48230959-7EF06344-5A4C-49A4-8665-5B84450CF6B9Q50026117-A814D33C-4183-44BE-A08D-2D25F6AEA008Q50648904-E30FC6FC-BECD-4552-9747-93FBF62D54A1Q51736517-69327749-68F3-41EE-B3F9-62AD10495811Q54958949-2D621988-EA68-40E7-9002-28DD7B83A889Q55420860-CE40F340-7846-4E33-9E60-43B244D418EFQ55472821-B3FBB481-9984-4565-B403-99BC486B7935Q58779250-2BA781F7-C5DA-4A9D-8B9A-A6E17197C0E3
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Parkinson's disease and systemic inflammation.
@en
Parkinson's disease and systemic inflammation.
@nl
type
label
Parkinson's disease and systemic inflammation.
@en
Parkinson's disease and systemic inflammation.
@nl
prefLabel
Parkinson's disease and systemic inflammation.
@en
Parkinson's disease and systemic inflammation.
@nl
P2860
P356
P1433
P1476
Parkinson's disease and systemic inflammation.
@en
P2093
Carina C Ferrari
Rodolfo Tarelli
P2860
P304
P356
10.4061/2011/436813
P577
2011-02-22T00:00:00Z